BioCentury | Mar 24, 2020
Product Development

Milestone says trial design trips up etripamil in tachycardia Phase III

Milestone’s at-home paroxysmal supraventricular tachycardia candidate did not meet its primary endpoint in the Phase III NODE-301 study, but the company believes the miss was due to trial design and that the data support efficacy....
BC Extra | Sep 13, 2019
Company News

Management tracks: Orchard, Black Diamond, ALK-Abelló, Menarini, Imvax, Rallybio, Milestone, MaaT and more

Jason Meyenburg has left Orchard Therapeutics plc (NASDAQ:ORTX) as CCO to become CEO of ophthalmic disease company Gemini Therapeutics Inc. (Cambridge, Mass.). Orchard President and CEO Mark Rothera will assume global commercial leadership responsibilities in...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
BioCentury | May 9, 2019
Finance

Cortexyme’s first-day pop leads IPO quartet amid choppy market

Despite unsettled market conditions, a foursome of biotechs priced their IPOs within their proposed ranges ahead of first-day trading Thursday and helped push the year-to-date tally of money raised in public market debuts well ahead...
BC Extra | Apr 29, 2019
Financial News

April 29 Quick Takes: Sirnaomics, Codiak, Cortexyme, Milestone, NextCure, Applied Therapeutics, Magenta

Sirnaomics closes $47M series C  RNAi therapeutics company Sirnaomics Inc. (Gaithersburg, Md.) raised $22 million in a series C2 round led by Hong Kong-based CR-CP Life Sciences Fund, closing out its series C round for...
BC Extra | Apr 16, 2019
Company News

Management tracks: Ginkgo Bioworks, KSQ, Milestone, Cerebral

Genetic engineering company Ginkgo Bioworks Inc. (Boston, Mass.) appointed Marijn Dekkers as chairman and strategic adviser. He was CEO of Bayer AG (Xetra:BAYN) and is currently chairman of Unilever plc (LSE:ULVR), Unilever N.V. (NYSE:UL) and...
BC Extra | Apr 12, 2019
Financial News

Flagship-backed Axcella seeking NASDAQ IPO

With its lead program headed for its first post-IND clinical study, Axcella proposed to raise up to $86.3 million in an IPO on NASDAQ. Axcella Health Inc. (Cambridge, Mass.) is developing a pipeline of endogenous...
BC Week In Review | Oct 26, 2018
Financial News

Milestone raises $80M to fund pivotal trial of at-home tachycardia therapy

Milestone Pharmaceuticals Inc. (Montreal, Quebec) raised $80 million in a series D on Oct. 25 to support a Phase III trial of its self-administered acute paroxysmal supraventricular tachycardia (PSVT) treatment, etripamil. Milestone began a Phase...
BC Extra | Oct 25, 2018
Financial News

Milestone raises $80M to fund pivotal trial of at-home tachycardia therapy

Milestone Pharmaceuticals Inc. (Montreal, Quebec) raised $80 million in a series D to support a Phase III trial of its self-administered acute paroxysmal supraventricular tachycardia (PSVT) treatment, etripamil. Milestone began a Phase III study of...
BC Extra | Oct 24, 2017
Company News

Management tracks: Five Prime, CytoSen

Cancer play Five Prime Therapeutics Inc. (NASDAQ:FPRX) promoted Aron Knickerbocker to president and CEO from COO, effective Jan. 1, 2018. He succeeds Lewis Williams, who will become executive chairman. Cell therapy company CytoSen Therapeutics Inc....
Items per page:
1 - 10 of 24
BioCentury | Mar 24, 2020
Product Development

Milestone says trial design trips up etripamil in tachycardia Phase III

Milestone’s at-home paroxysmal supraventricular tachycardia candidate did not meet its primary endpoint in the Phase III NODE-301 study, but the company believes the miss was due to trial design and that the data support efficacy....
BC Extra | Sep 13, 2019
Company News

Management tracks: Orchard, Black Diamond, ALK-Abelló, Menarini, Imvax, Rallybio, Milestone, MaaT and more

Jason Meyenburg has left Orchard Therapeutics plc (NASDAQ:ORTX) as CCO to become CEO of ophthalmic disease company Gemini Therapeutics Inc. (Cambridge, Mass.). Orchard President and CEO Mark Rothera will assume global commercial leadership responsibilities in...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
BioCentury | May 9, 2019
Finance

Cortexyme’s first-day pop leads IPO quartet amid choppy market

Despite unsettled market conditions, a foursome of biotechs priced their IPOs within their proposed ranges ahead of first-day trading Thursday and helped push the year-to-date tally of money raised in public market debuts well ahead...
BC Extra | Apr 29, 2019
Financial News

April 29 Quick Takes: Sirnaomics, Codiak, Cortexyme, Milestone, NextCure, Applied Therapeutics, Magenta

Sirnaomics closes $47M series C  RNAi therapeutics company Sirnaomics Inc. (Gaithersburg, Md.) raised $22 million in a series C2 round led by Hong Kong-based CR-CP Life Sciences Fund, closing out its series C round for...
BC Extra | Apr 16, 2019
Company News

Management tracks: Ginkgo Bioworks, KSQ, Milestone, Cerebral

Genetic engineering company Ginkgo Bioworks Inc. (Boston, Mass.) appointed Marijn Dekkers as chairman and strategic adviser. He was CEO of Bayer AG (Xetra:BAYN) and is currently chairman of Unilever plc (LSE:ULVR), Unilever N.V. (NYSE:UL) and...
BC Extra | Apr 12, 2019
Financial News

Flagship-backed Axcella seeking NASDAQ IPO

With its lead program headed for its first post-IND clinical study, Axcella proposed to raise up to $86.3 million in an IPO on NASDAQ. Axcella Health Inc. (Cambridge, Mass.) is developing a pipeline of endogenous...
BC Week In Review | Oct 26, 2018
Financial News

Milestone raises $80M to fund pivotal trial of at-home tachycardia therapy

Milestone Pharmaceuticals Inc. (Montreal, Quebec) raised $80 million in a series D on Oct. 25 to support a Phase III trial of its self-administered acute paroxysmal supraventricular tachycardia (PSVT) treatment, etripamil. Milestone began a Phase...
BC Extra | Oct 25, 2018
Financial News

Milestone raises $80M to fund pivotal trial of at-home tachycardia therapy

Milestone Pharmaceuticals Inc. (Montreal, Quebec) raised $80 million in a series D to support a Phase III trial of its self-administered acute paroxysmal supraventricular tachycardia (PSVT) treatment, etripamil. Milestone began a Phase III study of...
BC Extra | Oct 24, 2017
Company News

Management tracks: Five Prime, CytoSen

Cancer play Five Prime Therapeutics Inc. (NASDAQ:FPRX) promoted Aron Knickerbocker to president and CEO from COO, effective Jan. 1, 2018. He succeeds Lewis Williams, who will become executive chairman. Cell therapy company CytoSen Therapeutics Inc....
Items per page:
1 - 10 of 24